D 
Dexcom DXCM · USD
Health Care · Health Care Equipment & Supplies · US listing · 🇺🇸 United States
S&P 500Nasdaq-100
81.07
+2.09%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in USD, from our data supplier.
Revenue
$4.66bn
FY2016FY2025
Net income
$836.3m
FY2016FY2025
Free cash flow
$1.08bn
FY2016FY2025
Shareholders' equity
$2.75bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.66bn | $4.03bn | $3.62bn | $2.91bn | $2.45bn | $1.93bn | $1.48bn | $1.03bn | $718.5m | $573.3m |
| Gross profit | $2.80bn | $2.44bn | $2.29bn | $1.88bn | $1.68bn | $1.28bn | $931.5m | $663.9m | $492.1m | $378.4m |
| Research and development | $599.1m | $552.4m | $505.8m | $484.2m | $604.2m | $359.9m | $273.5m | $417.4m | $185.4m | $156.1m |
| Operating income | $911.8m | $600.0m | $597.7m | $391.2m | $265.8m | $299.5m | $142.3m | −$186.3m | −$39.1m | −$64.6m |
| Net income | $836.3m | $576.2m | $541.5m | $341.2m | $216.9m | $493.6m | $101.1m | −$127.1m | −$50.2m | −$65.6m |
| Diluted earnings per share | 2.10 | 1.42 | 1.30 | 0.80 | 0.56 | 1.27 | 0.27 | -0.36 | -0.14 | -0.19 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $6.34bn | $6.48bn | $6.26bn | $5.39bn | $4.93bn | $4.29bn | $2.40bn | $1.92bn | $904.1m | $402.8m |
| Cash and short-term investments | $2.00bn | $2.58bn | $2.72bn | $2.46bn | $2.73bn | $2.71bn | $1.53bn | $1.39bn | $548.6m | $123.7m |
| Total liabilities | $3.59bn | $4.38bn | $4.20bn | $3.26bn | $2.89bn | $2.46bn | $1.51bn | $1.25bn | $484.7m | $119.0m |
| Debt | $1.26bn | $2.51bn | $2.50bn | $2.03bn | $2.04bn | $1.73bn | $1.07bn | $1.02bn | $334.3m | $6.0m |
| Shareholders' equity | $2.75bn | $2.10bn | $2.07bn | $2.13bn | $2.04bn | $1.83bn | $882.6m | $663.3m | $419.4m | $283.8m |
| Shares outstanding | 399m | 407m | 416m | 426m | 388m | 390m | 371m | 355m | 348m | 338m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | $1.44bn | $989.5m | $748.5m | $669.5m | $442.5m | $475.6m | $314.5m | $123.2m | $92.0m | $56.2m |
| Capital spending | −$363.5m | −$358.8m | −$236.6m | −$364.8m | −$389.2m | −$199.0m | −$180.0m | −$67.1m | −$66.0m | −$55.7m |
| Free cash flow | $1.08bn | $630.7m | $511.9m | $304.7m | $53.3m | $276.6m | $134.5m | $56.1m | $26.0m | $500,000 |
| Dividends paid | — | — | −$1.23bn | — | — | — | — | — | — | — |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.31bn | $1.19bn | $1.26bn | $1.21bn | $1.16bn | $1.04bn | $1.11bn | $994.2m |
| Gross profit | $830.0m | $750.3m | $792.7m | $731.4m | $688.8m | $589.0m | $655.8m | $593.8m |
| Operating income | $318.3m | $255.3m | $323.0m | $242.5m | $212.6m | $133.7m | $188.9m | $152.0m |
| Net income | $249.1m | $199.5m | $267.3m | $283.8m | $179.8m | $105.4m | $151.7m | $134.6m |
| Diluted earnings per share | 0.64 | 0.51 | 0.67 | 0.71 | 0.45 | 0.26 | 0.37 | 0.33 |
| Cash from operations | $269.0m | $525.0m | $294.0m | $659.0m | $303.0m | $183.0m | $301.0m | $199.0m |
| Capital spending | −$84.0m | −$76.0m | −$101.0m | −$80.0m | −$94.0m | −$87.0m | −$124.0m | −$111.0m |
| Free cash flow | $185.0m | $449.0m | $193.0m | $579.0m | $209.0m | $96.0m | $177.0m | $88.0m |
| Total assets | $6.46bn | $6.63bn | $6.34bn | $7.50bn | $7.33bn | $6.75bn | $6.48bn | $6.35bn |
| Cash and short-term investments | $1.95bn | $2.42bn | $2.00bn | $3.32bn | $2.93bn | $2.70bn | $2.58bn | $2.49bn |
| Debt | $1.26bn | $1.26bn | $1.26bn | $2.47bn | $2.47bn | $2.47bn | $2.46bn | $2.46bn |
| Shareholders' equity | $2.62bn | $2.96bn | $2.75bn | $2.73bn | $2.57bn | $2.27bn | $2.10bn | $1.98bn |
Financial ratios
Data as of 23 Sept 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Gross margin | 60.1% | 60.5% | 63.2% | 64.7% | 68.6% | 66.4% |
| Operating margin | 19.6% | 14.9% | 16.5% | 13.4% | 10.9% | 15.5% |
| Net margin | 17.9% | 14.3% | 14.9% | 11.7% | 8.9% | 25.6% |
| Return on equity | 30.5% | 27.4% | 26.2% | 16.0% | 10.6% | 27.0% |
| Return on assets | 13.2% | 8.9% | 8.6% | 6.3% | 4.4% | 11.5% |
| Free cash flow yield | 5.1% | 3.7% | 2.6% | 2.7% | 2.4% | 1.9% |
| Revenue growth | 15.6% | 11.3% | 24.5% | 18.8% | 27.1% | 30.5% |
| Earnings growth | 45.1% | 6.4% | 58.7% | 57.3% | -56.1% | 388.2% |
| Current ratio | 1.88x | 1.47x | 2.84x | 1.99x | 5.11x | 5.58x |
| Debt to equity | 0.46x | 1.17x | 1.19x | 0.93x | 0.84x | 0.92x |
| Equity ratio | 43.3% | 32.4% | 33.0% | 39.5% | 41.4% | 42.6% |
| Interest coverage | 49.83x | 31.58x | 29.44x | 21.03x | 14.14x | 3.54x |
| R&D as a share of sales | 12.9% | 13.7% | 14.0% | 16.6% | 24.7% | 18.7% |
| Buybacks as a share of market value | 1.9% | 2.2% | 2.3% | -9.8% | 0.5% | -5.1% |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 17.0% | 19.3% | 27.8% |
| Operating income | 32.6% | 24.9% | — |
| Net income | 34.8% | 11.1% | — |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 60.3% | 61.8% | 63.1% | 63.5% |
| Operating margin | 17.4% | 16.4% | 15.6% | 12.0% |
| Net margin | 16.2% | 15.1% | 15.3% | 11.8% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 31.7 | 54.9 | 56.6 | 83.9 | 142.5 | 43.3 | 119.2 | -49.6 | -59.0 | -45.7 |
| Price to sales | 5.7 | 7.8 | 8.4 | 9.8 | 12.6 | 11.1 | 8.2 | 6.1 | 4.1 | 5.2 |
Market value over time
31 Oct 2016 to 22 Sept 2026, in USD
$6.58bn$35.08bn
Share price return
Finished calendar years
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Return | -12% | 3% | 10% | -18% | 56% | 63% | 94% | 94% | -11% | -19% |
Dividends and splits
Per share, in the currency the company pays
Paid for 0 years.
- 4-for-1 split · 13 Jun 2022
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.